TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23380213

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal instrument-based manipulative treatments (9 treatments over 2 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nontreatment (asymptomatic group, n = 10, 6 males, 4 females)
Number of subjects: 11
Study: 21955527

Group type: EXPERIMENTAL
Intervention: Mixed invitation (paper-based questionnaire together with log-in details for Web-based questionnaire)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Web-only invitation (log-in details only)
Number of subjects: 277
Study: 19535430

Group type: EXPERIMENTAL
Intervention: Food plus water intake
Number of subjects: 35

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 35
Study: 16546771

Group type: EXPERIMENTAL
Intervention: Moderately intensive basketball training program for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (home respiratory exercise program)
Number of subjects: 62
Study: 12788859

Group type: EXPERIMENTAL
Intervention: Octreotide (5-15 microg/kg x d s.c.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10819321

Group type: EXPERIMENTAL
Intervention: Low fall-related self-efficacy (FES score < or = 75)
Number of subjects: 528

Group type: COMPARATOR
Intervention: High fall-related self-efficacy (FES score = 100)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Poor fall-related self-efficacy
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Nonfallers afraid of falling
Number of subjects: 528
Study: 8838483

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol (EE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol (EE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (20 micrograms EE and 30 micrograms EE)
Number of subjects: 40
Study: 1336735

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3938681

Group type: EXPERIMENTAL
Intervention: Transderm‐Nitro (TDN)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nitro‐Dur (ND)
Number of subjects: 65
Study: 29983189

Group type: EXPERIMENTAL
Intervention: Standard ointment dressings
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mepitel Ag®
Number of subjects: 96
Study: 30149076

Group type: EXPERIMENTAL
Intervention: Combined Physical Activity and Sleep Health intervention
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Sleep Health-Only intervention
Number of subjects: 275

Group type: COMPARATOR
Intervention: Wait List Control group
Number of subjects: 275
Study: 26685010

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone
Number of subjects: 762
Study: 25332325

Group type: EXPERIMENTAL
Intervention: Low-genistein (LG) supplement (100 mg isoflavones/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-genistein (HG) supplement (100 mg isoflavones/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 57

Group type: COMPARATOR
Intervention: Isoflavone supplementation
Number of subjects: 57
Study: 22378566

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Golimumab (combined 50 mg and 100 mg)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 405
Study: 20551021

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (Group F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Periarticular infiltration of local anaesthetic (Group I)
Number of subjects: 40
Study: 18635219

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 856

Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 856
Study: 16207627

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 179

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 179
Study: 11792874

Group type: EXPERIMENTAL
Intervention: Nurse-delivered educational package
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (simple advice regarding NSAID use)
Number of subjects: 222
Study: 10412878

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily for 16 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg daily for 16 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy elderly men (cross-sectional study)
Number of subjects: 50
Study: 7600840

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 10

Group type: COMPARATOR
Intervention: Corticosteroids (low-dose vs. high-dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Corticosteroids in patients with Gram-negative infection
Number of subjects: 10
Study: 2393268

Group type: EXPERIMENTAL
Intervention: 200 mg cefpodoxime proxetil (single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg cefpodoxime proxetil (steady state, after 5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg cefpodoxime proxetil (single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg cefpodoxime proxetil (steady state, after 5 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both dosing regimens (200 mg and 400 mg)
Number of subjects: 16
Study: 7290471

Group type: EXPERIMENTAL
Intervention: Silymarin (420 mg/die/os)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30952509

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Zinc + Multivitamins
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study: 28440888

Group type: EXPERIMENTAL
Intervention: Consecutive dual-task training (gait and cognitive tasks trained separately)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Integrated dual-task training (gait and cognitive tasks trained simultaneously)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 121
Study: 25950503

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream, 5% (n=468)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Vehicle control cream (n=464)
Number of subjects: 932
Study: 24053647

Group type: EXPERIMENTAL
Intervention: HTK cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: WBC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HTK with topical cooling
Number of subjects: 60

Group type: COMPARATOR
Intervention: HTK without topical cooling
Number of subjects: 60
Study: 21355946

Group type: EXPERIMENTAL
Intervention: Iyengar yoga practice (90 min twice weekly for 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Wait-listed, noninterventional control group (n = 9)
Number of subjects: 18
Study: 19787222

Group type: EXPERIMENTAL
Intervention: Estrogen receptor-beta (ER-beta) expression
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ER-beta expression
Number of subjects: 80
Study: 17096171

Group type: EXPERIMENTAL
Intervention: Intraarticular 100 mg of tramadol in 20 ml normal saline and periarticular incisional injection of 10 ml bupivacaine 0.5% (Group TB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intraarticular 20 ml 0.25% and periarticular incisional 10 ml 0.5% bupivacaine injections (Group BB)
Number of subjects: 74
Study: 12439083

Group type: EXPERIMENTAL
Intervention: Carbohydrate (C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 98
Study: 10726235

Group type: EXPERIMENTAL
Intervention: Trazodone (mean once‐daily dose 111.5 +/- 36.3 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clorazepate (mean once‐daily dose 17.5 +/- 7.5 mg)
Number of subjects: 18
Study: 8746642

Group type: EXPERIMENTAL
Intervention: Low sodium, high potassium, high magnesium salt (mineral salt)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Common salt (control)
Number of subjects: 89
Study: 2029287

Group type: EXPERIMENTAL
Intervention: Rectally administered diazepam (R‐DZP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-users of R‐DZP
Number of subjects: 41
Study: 6459190

Group type: EXPERIMENTAL
Intervention: Tice lyophilized BCG
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pasteur lyophilized BCG
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pasteur fresh-frozen BCG
Number of subjects: 130

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BCG treatments (all types)
Number of subjects: 130
Study: 29800372

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) after Abaloparatide (ABL)
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Alendronate (ALN) after Placebo (PBO)
Number of subjects: 1139
Study: 28756050

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duodenal switch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between gastric bypass and duodenal switch
Number of subjects: 60
Study: 26262904

Group type: EXPERIMENTAL
Intervention: Short-acting oral methylphenidate, taken two or three times daily; each dose ranged between 0.3 and 1.0 mg/kg.
Number of subjects: 154
Study: 23218404

Group type: EXPERIMENTAL
Intervention: Bryophyllum pinnatum (BP) 350 mg/day (3×2 capsules)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 22003163

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Late‐Life Function and Disability Instrument (LLFDI)
Number of subjects: 137
Study: 18427025

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 257
Study: 16555023

Group type: EXPERIMENTAL
Intervention: Endoscopic India ink tattooing (n = 21; tattooed group, TG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional localization methods (n = 26; non‐tattooed group, NTG)
Number of subjects: 47
Study: 12510801

Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for a median of 19 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (with calcium and vitamin D)
Number of subjects: 0
Study: 11072392

Group type: EXPERIMENTAL
Intervention: Coping-skills Relapse Prevention (RP) treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Health Belief Model (HBM) treatment
Number of subjects: 160
Study: 7576392

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrices (1100 ppm F-)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrices (2800 ppm F-)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyampholyte-NaF delivery system (1100 ppm F-)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (including fluoride dentifrices)
Number of subjects: 0
Study: 2254698

Group type: EXPERIMENTAL
Intervention: Customized software exercise electrocardiographic program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two experienced cardiologists without computerized measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Computerized measurements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-computerized measurements
Number of subjects: 20
Study: 6776974

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min followed by low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min followed by high-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min
Number of subjects: 13
Study: 30905130

Group type: EXPERIMENTAL
Intervention: Adjunctive 1,000 mg/day of mangosteen pericarp
Number of subjects: 150

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 150
Study: 30030720

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 24 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks in patients with NS5A RASs
Number of subjects: 117
Study: 26762282

Group type: EXPERIMENTAL
Intervention: Sailuotong (SLT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24452498

Group type: EXPERIMENTAL
Intervention: Attitudinal discussion
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Informative talk
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Role play
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Fear induction
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Informative website
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 167
Study: 22196196

Group type: EXPERIMENTAL
Intervention: Light extrusive forces (25 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heavy extrusive forces (225 g)
Number of subjects: 10
Study: 21058477

Group type: EXPERIMENTAL
Intervention: Penetration needling combined with electroacupuncture on the back shu points and Governor Vessel points for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ibuprofen capsules for 30 days
Number of subjects: 60
Study: 18186237

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: COPD diagnosis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Current smoking status
Number of subjects: 400
Study: 15774170

Group type: EXPERIMENTAL
Intervention: Tight control of blood glucose by intensive insulin therapy (maintenance of blood glucose at a level between 4.4 and 6.1 mmol/L)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tight control of blood glucose by intensive insulin therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment (maintenance of glucose at a level between 10.0 and 11.1 mmol/L)
Number of subjects: 54
Study: 11821798

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with chemotherapy and radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra- or postoperative hyperthermia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperthermia for unresectable or local recurrent rectal cancer
Number of subjects: 0
Study: 10221191

Group type: EXPERIMENTAL
Intervention: Subtenon anesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 25
Study: 7602364

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for intermediate-grade lymphomas
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiation therapy or therapy for low-grade lymphoma or Hodgkin's disease
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for intermediate-grade lymphoma
Number of subjects: 44

Group type: COMPARATOR
Intervention: Other therapies (including salvage therapies)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy directed at large-cell lymphomas
Number of subjects: 44
Study: 30870102

Group type: EXPERIMENTAL
Intervention: Single session of Behavioural Activation followed by 8 weeks of daily SMS messages (INT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single (attention control) session focused on the importance of motivation followed by 8 weeks of motivational SMS messages (MOT)
Number of subjects: 59
Study: 30234568

Group type: EXPERIMENTAL
Intervention: Mean storage age of blood transfusions (25.6 +/- 10.2 days)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Proportion of very old blood (mean of 5.3 +/- 10.7 units)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Mean storage age of blood transfusions
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Proportion of very old blood
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Blood transfusions (6,786 total)
Number of subjects: 303
Study: 28766403

Group type: EXPERIMENTAL
Intervention: Diabetes HealthSense website usage after group education session
Number of subjects: 311

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Diabetes HealthSense website usage
Number of subjects: 311
Study: 26275599

Group type: EXPERIMENTAL
Intervention: GentleWave System (GWS) treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional rotary instrumentation and needle irrigation
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study: 22729012

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1.5 g mixed in 100 cc of saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intra-articular tranexamic acid (1.5 g mixed in 100 cc of saline)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (normal saline administered into the knee joint cavity and intravenously)
Number of subjects: 150
Study: 21613336

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 75
Study: 19961341

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 106
Study: 16005883

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Simvastatin
Number of subjects: 115
Study: 15224471

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients with NMNG and thyroid carcinoma
Number of subjects: 80
Study: 11725155

Group type: COMPARATOR
Intervention: HRT 1 (1 mg of 17beta‐oestradiol per day continuously plus 0.025 mg gestodene on days 17‐28 of each 4‐week cycle)
Number of subjects: 226

Group type: COMPARATOR
Intervention: HRT 2 (1 mg of 17beta‐oestradiol per day continuously plus gestodene in each third cycle only)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: No HRT
Number of subjects: 226
Study: 9165186

Group type: EXPERIMENTAL
Intervention: 1 mg fluoride daily in the form of a tablet
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study: 7896628

Group type: EXPERIMENTAL
Intervention: 40 degrees C and 20% relative humidity (T40)
Number of subjects: 12
Study: 3309479

Group type: EXPERIMENTAL
Intervention: Group I (one-dose protocol): All protamine infused within 10 minutes after termination of cardiopulmonary bypass.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II (two-dose protocol): 75% of the calculated protamine dose infused within 10 minutes after termination of bypass, remainder after transfusion of all blood in the heart-lung machine.
Number of subjects: 20
Study: 29777714

Group type: EXPERIMENTAL
Intervention: NMES (15Hz, pulse width 200μs) applied to supraspinatus and deltoids for 4 weeks, 20 sessions of 1 hour each.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TENS (100Hz, pulse width 100μs) used on the same areas for 4 weeks, 20 sessions of 1 hour each.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group received routine rehabilitation without stimulation.
Number of subjects: 90
Study: 27228512

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (DEX I group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 µg/kg (DEX II group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2 µg/kg (DEX III group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Meperidine 0.4 mg/kg (meperidine group)
Number of subjects: 120
Study: 24286284

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 62
Study: 22353612

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; α‐lipoic acid, 600 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 19826827

Group type: EXPERIMENTAL
Intervention: Voice training program for 4 weeks
Number of subjects: 0
Study: 18953651

Group type: EXPERIMENTAL
Intervention: Chemoendocrine treatment
Number of subjects: 893

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 893
Study: 15842141

Group type: EXPERIMENTAL
Intervention: Aitongping capsule (ATP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac (Control)
Number of subjects: 60
Study: 12851275

Group type: EXPERIMENTAL
Intervention: Promensil (82 mg of total isoflavones per day)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Rimostil (57 mg of total isoflavones per day)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 10229276

Group type: EXPERIMENTAL
Intervention: Silicone insert
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Rubber insert
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Felt insert
Number of subjects: 236

Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Custom orthosis
Number of subjects: 236
Study: 8707387

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Number of subjects: 127
Study: 1746418

Group type: EXPERIMENTAL
Intervention: Oral controlled-release mononitrate for 1 month
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Oral captopril for 1 month
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium for 24 hours
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo for oral controlled-release mononitrate
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo for oral captopril
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Open control (no infusion) for intravenous magnesium
Number of subjects: 10000
Study: 6137945

Group type: EXPERIMENTAL
Intervention: Beta blockers (e.g., practolol, timolol, propranolol)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Timolol (Norwegian Multicenter Study)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Propranolol (Beta‐Blocker Heart Attack Trial)
Number of subjects: 8000